E-LIB Suche - Ergebnisse für: Viani, Rolando

1

1284. Outcomes by Baseline Pathogens and Susceptibility in ..:

Thompson III, George R ; Horcajada, Juan P ; Locke, Jeffrey B...
Open Forum Infectious Diseases. 7 (2020) Supplement_1 - p. S657-S658 , 2020

Link: https://doi.org/10.1093/..

2

Long-Term Safety and Efficacy of Dolutegravir in HIV Treatm..:

Viani, Rolando ; Alvero, Carmelita ; Fenton, Terence...
Open Forum Infectious Diseases. 2 (2015) suppl_1 - p. , 2015

Link: https://doi.org/10.1093/..

3

1793Morbidity and Mortality of a Large Cohort of Peruvian H..:

Baker, Amira ; Bayer, Angela ; Deville, Jaime..
Open Forum Infectious Diseases. 1 (2014) suppl_1 - p. S61-S61 , 2014

Link: https://doi.org/10.1093/..

4

Profile of etravirine in the treatment of HIV in pediatrics:

Viani, Rolando ; Dehority, Walter
Pediatric Health, Medicine and Therapeutics. , 2013

Link: https://doi.org/10.2147/..

5

Role of etravirine in the management of treatment-experienc..:

Viani, Rolando
HIV/AIDS - Research and Palliative Care. , 2010

Link: https://doi.org/10.2147/..

6

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) ..:

Hobbs, F. D. Richard ; Montgomery, Hugh ; Padilla, Francisco...
Infectious Diseases and Therapy. 12 (2023) 9 - p. 2269-2287 , 2023

Link: https://doi.org/10.1007/..

7

1924. Outpatient Treatment With the SARS-CoV-2–Neutralizing..:

Richard Hobbs, F D ; Montgomery, Hugh ; Padilla, Francisco...
Open Forum Infectious Diseases. 9 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

8

1918. Impact of the SARS-CoV-2–Neutralizing Antibody Combin..:

Campos, Jesus Abraham Simón ; Arbetter, Douglas ; Montgomery, Hugh...
Open Forum Infectious Diseases. 9 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

9

Efficacy and safety of intramuscular administration of tixa..:

Montgomery, Hugh ; Hobbs, F D Richard ; Padilla, Francisco...
The Lancet Respiratory Medicine. 10 (2022) 10 - p. 985-996 , 2022

Link: https://doi.org/10.1016/..

10

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Dou..:

Thompson III, George R ; Soriano, Alex ; Skoutelis, Athanasios...
Clinical Infectious Diseases. 73 (2020) 11 - p. e3647-e3655 , 2020

Link: https://doi.org/10.1093/..

11

Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coad..:

Kosloski, Matthew P ; Oberoi, Rajneet ; Wang, Stanley...
The Journal of Infectious Diseases. 221 (2019) 2 - p. 223-231 , 2019

Link: https://doi.org/10.1093/..

12

Long-Term Safety and Efficacy of Dolutegravir in Treatment-..:

The P1093 Study Team ; Wiznia, Andrew ; George, Kathleen...
Journal of the Pediatric Infectious Diseases Society. 9 (2019) 2 - p. 159-165 , 2019

Link: https://doi.org/10.1093/..

13

Child, Caregiver, and Health Care Provider Perspectives and..:

Baker, Amira Noori ; Bayer, Angela Marie ; Kolevic, Lenka...
Journal of the International Association of Providers of AIDS Care (JIAPAC). 17 (2018) - p. 232595741775225 , 2018

Link: https://doi.org/10.1177/..

14

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir..:

Leung, Daniel H. ; Wirth, Stefan ; Yao, Betty B....
Hepatology Communications. 2 (2018) 11 - p. 1311-1319 , 2018

Link: https://doi.org/10.1002/..

15

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients..:

Rockstroh, Jürgen K ; Lacombe, Karine ; Viani, Rolando M...
Clinical Infectious Diseases. 67 (2018) 7 - p. 1010-1017 , 2018

Link: https://doi.org/10.1093/..